Company Overview and News
Mumbai: Indian shipping firms are threatening to “flag out” and register in foreign territories if the government removes one of the last few protections that they still enjoy. Great Eastern Shipping and Shreyas Shipping —two of the largest private shipping lines in the country—are mulling the option of moving to more tax-friendly jurisdictions as the government gradually removes these benefits.
Great Eastern Shipping Ltd today said its board will next month decide on raising up to Rs 1,000 crore through private placement of non-convertible debentures (NCDs).
Great Eastern Shipping Company has taken delivery of a second-hand very large gas carrier ‘Jag Viraat’ (2007 built) of about 81,617 cbm. The company had contracted to buy the vessel earlier this month. GE Shipping’s current fleet stands at 48 vessels, comprising 33 tankers (12 crude carriers, 17 product tankers, 4 LPG carriers) and 15 dry bulk carriers (1 capesize, 8 Kamsarmax, 6 Supramax) with an average age of 10.
3:30 pm Market Closing: Benchmark indices continued to trade higher for second consecutive session, with the Sensex rising 107.98 points to 33,174.39, tracking positive move in global equities.
500325 533096 TCHQY ICLQY 511218 TALBROAUTO BJJQY EICHERMOT RLNIY GLENMARK JETAIRWAYS 532702 511196 532822 532942 CNRYY KNRCON 500182 AXBA BAJAJFINSV FORTIS 500180 500620 CANBK SSWL 500188 HINDZINC 532938 IDBI RIFS PUNJLLOYD 539336 SRTRANSFIN 500390 532388 505200 IDFCBANK AXISBANK 505160 JMCPROJECT RIGD HEROMOTOCO BHARTIARTL 500034 TATAMETALI AXBKY RELINFRA ICICIBANK HDB HRTQY IOB GESHIP CAPF GSPL VINATIORGA 532755 S68 539437 532483 SRRQY 522287 GAILF SBAZ GICHSGFIN 517496 SYNGENE RICOHQ SPXCF RELEY AXB RELFF 539268 CANFINHOME 511676 TECHM SPXCY GUJGAS BAJFINANCE TATASTEEL TATLY GAILY RIFA 513262 RELIANCE 532617 HNDZY 532978 BHRQY GLKQY 532215 500470 524200 522263 HDFCBANK UBNC ECQRY 500116 IBN 513434 532843 532179 532454 TTST 532693 532296 CRPKY 532174 IDEA KALPATPOWR CORPBANK ADANIPOWER
10h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
10h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
12h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...